SG11202007441TA - Closed-system manufacturing process for car-t cells - Google Patents
Closed-system manufacturing process for car-t cellsInfo
- Publication number
- SG11202007441TA SG11202007441TA SG11202007441TA SG11202007441TA SG11202007441TA SG 11202007441T A SG11202007441T A SG 11202007441TA SG 11202007441T A SG11202007441T A SG 11202007441TA SG 11202007441T A SG11202007441T A SG 11202007441TA SG 11202007441T A SG11202007441T A SG 11202007441TA
- Authority
- SG
- Singapore
- Prior art keywords
- car
- cells
- closed
- manufacturing process
- system manufacturing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862627129P | 2018-02-06 | 2018-02-06 | |
PCT/US2019/016497 WO2019156926A1 (en) | 2018-02-06 | 2019-02-04 | Closed-system manufacturing process for car-t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007441TA true SG11202007441TA (en) | 2020-09-29 |
Family
ID=67548563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007441TA SG11202007441TA (en) | 2018-02-06 | 2019-02-04 | Closed-system manufacturing process for car-t cells |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210040448A1 (en) |
EP (1) | EP3749337A4 (en) |
JP (1) | JP2021512618A (en) |
CN (1) | CN111801104A (en) |
AU (1) | AU2019217363A1 (en) |
BR (1) | BR112020015889A2 (en) |
CA (1) | CA3090148A1 (en) |
IL (1) | IL276472A (en) |
SG (1) | SG11202007441TA (en) |
WO (1) | WO2019156926A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220220504A1 (en) * | 2019-05-28 | 2022-07-14 | Miltenyi Biotec B.V. & Co. KG | Method for Generation of Genetically Modified T Cells |
JP7339528B2 (en) | 2019-10-25 | 2023-09-06 | ノイルイミューン・バイオテック株式会社 | Genetically modified cell production system |
WO2021148019A1 (en) * | 2020-01-22 | 2021-07-29 | 科济生物医药(上海)有限公司 | Method for transducing cells with viral vector |
US20210387176A1 (en) * | 2020-06-16 | 2021-12-16 | Sani-Tech West, Inc. | Closed fluid receiving and sampling container |
WO2024081167A1 (en) * | 2022-10-10 | 2024-04-18 | Kite Pharma, Inc. | New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX359513B (en) * | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | METHOD and COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY. |
US20140212398A1 (en) * | 2011-09-08 | 2014-07-31 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
TWI654206B (en) * | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
ES2708584T3 (en) * | 2014-04-24 | 2019-04-10 | Miltenyi Biotec Gmbh | Method for the automated generation of genetically modified T cells |
US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
CN110234756A (en) * | 2017-01-18 | 2019-09-13 | F1肿瘤医学公司 | The method and application thereof of transduction and amplification immunocyte |
-
2019
- 2019-02-04 WO PCT/US2019/016497 patent/WO2019156926A1/en unknown
- 2019-02-04 CA CA3090148A patent/CA3090148A1/en active Pending
- 2019-02-04 US US16/965,964 patent/US20210040448A1/en active Pending
- 2019-02-04 AU AU2019217363A patent/AU2019217363A1/en active Pending
- 2019-02-04 BR BR112020015889-5A patent/BR112020015889A2/en not_active Application Discontinuation
- 2019-02-04 JP JP2020542568A patent/JP2021512618A/en active Pending
- 2019-02-04 SG SG11202007441TA patent/SG11202007441TA/en unknown
- 2019-02-04 EP EP19751005.0A patent/EP3749337A4/en active Pending
- 2019-02-04 CN CN201980016239.9A patent/CN111801104A/en active Pending
-
2020
- 2020-08-03 IL IL276472A patent/IL276472A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210040448A1 (en) | 2021-02-11 |
AU2019217363A1 (en) | 2020-08-20 |
CN111801104A (en) | 2020-10-20 |
JP2021512618A (en) | 2021-05-20 |
EP3749337A4 (en) | 2021-11-03 |
BR112020015889A2 (en) | 2020-12-15 |
CA3090148A1 (en) | 2019-08-15 |
EP3749337A1 (en) | 2020-12-16 |
WO2019156926A1 (en) | 2019-08-15 |
IL276472A (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276600A (en) | Methods for manufacturing t cells | |
PL3444889T3 (en) | Method for manufacturing battery module | |
FI3636753T3 (en) | Method for manufacturing dna-edited eukaryotic cell | |
GB201602259D0 (en) | Integrated Lithium production process | |
IL276597A (en) | Method for producing low-antigenic cell | |
IL276472A (en) | Closed-system manufacturing process for car-t cells | |
EP3712967C0 (en) | Method for manufacturing solar cell | |
EP3203570A4 (en) | Method for manufacturing electrolyte material | |
GB201817166D0 (en) | Multi-junction device production process | |
PL3605703T3 (en) | Production method for lgps-based solid electrolyte | |
GB201707143D0 (en) | Method for producing cells | |
IL254704A0 (en) | Infrared-transmitting glass suitable for mold forming | |
PL3735354T3 (en) | Methods for manufacturing panels | |
HUE056390T2 (en) | Production method for solid electrolyte having li3ps4 | |
EP3518322A4 (en) | Production method for film-clad battery | |
EP3316324A4 (en) | Secondary battery manufacturing method | |
EP3573163A4 (en) | Method for manufacturing mono cell | |
IL280556A (en) | Cell production method | |
IL283085A (en) | Improved t cell manufacturing process | |
EP3683863A4 (en) | Method for manufacturing lead storage cell | |
IL274330A (en) | Process for producing a t cell composition | |
EP3196969A4 (en) | Method for manufacturing secondary battery | |
HK1254798A1 (en) | Process for manufacturing 1-cyclopropyl-naphthalenes | |
LT3682485T (en) | Process for manufacturing a homojunction photovoltaic cell | |
SG11201803333RA (en) | Method for manufacturing a hybrid structure |